Which is better for the E Fund?

E Fund has more than 40 index funds, which have always performed well and received wide attention from the industry. According to the fund performance data of the first half of 20 15, the performance champion of the index fund is E Fund Growth Enterprise Market ETF, with a net increase of 88.38%. So which one is better for E Fund?

Personally recommend E Fund CSI 300 Pharmaceutical ETF, the first industry ETF under E Fund. The Fund takes the Shanghai and Shenzhen 300 Pharmaceutical Index as the tracking target, and provides investors with an investment tool in the pharmaceutical industry through indexed investment management. The fund belongs to a cross-market ETF, which adopts the cash substitution mode of Shanghai Stock Exchange and can realize T+0 fast trading.

The development prospect of the pharmaceutical industry is improving: with the acceleration of China's aging population, the strong demand of consumers for medical care will promote the rapid development of the pharmaceutical industry. Take the United States and Japan as examples. At the peak of its pharmaceutical industry, pharmaceutical stocks accounted for 27% and 1 1% of its domestic stock market respectively. Even if it falls back to 13% and 10% respectively, it is still far higher than the domestic level of 5%. The Twelfth Five-Year Plan of China Municipal Government proposes that by 20 15, a basic medical and health system covering urban and rural residents will be initially established, and the development goal of "medical care for all" will be basically realized. The government will continue to increase investment in medical and other fields, and the pharmaceutical industry has huge room for future development.

The pharmaceutical sector has a reasonable valuation and good growth: the P/E ratio of the pharmaceutical sector is at a medium and high level among all sectors of the Shanghai and Shenzhen 300 Index. E Fund's valuation is reasonable, and high growth can support high premium to some extent.